Compare Core Scientific Inc (CORZ) vs Humana Inc (HUM) Price & Performance

CORZ trades at $21.30, up 9.57% in the last 24 hours, showing strong momentum despite a bearish technical signal. The stock faces fundamental challenges with a net income margin of -324.9% and negative EPS misses, but recent developments include a significant partnership with AMD for up to 2.5 gigawatts of data center capacity, potentially driving future revenue growth. Analyst sentiment remains overwhelmingly positive with 86% buy ratings and a consensus price target of $35.88.

The outlook for CORZ hinges on executing its AI infrastructure strategy, with the AMD deal offering substantial upside if successfully monetized. Key risks include persistent cash burn, competitive pressures, and reliance on long-term contracts. Investors should weigh the high growth potential against the current lack of profitability and volatile stock performance.

Humana (HUM) trades at $385.47, up 0.12% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue growth remains robust, reaching $129.66B in 2025, though net income margins have compressed to 0.88%. Recent news highlights leadership changes and Medicaid contract wins, while analyst consensus leans Hold with a $409.93 price target.

Outlook is mixed: Medicare Advantage margin expansion plans and cost controls offer upside, but regulatory pressures and margin erosion pose risks. The stock presents a cautious opportunity for investors betting on operational turnaround, with technical support near $382.